AXXAM

info@axxam.com

News

Axxam announces appointment of Ciriaco Maraschiello as Chief Executive Officer

  • 10 January 2025

Milan, Italy – Axxam, a leading innovation partner for life sciences research, is pleased to announce that its Board of Directors has appointed Dr. Ciriaco Maraschiello, who previously served as Chief Operating Officer (COO), as Chief Executive Officer (CEO), effective January 1, 2025. Dr. Ciriaco Maraschiello succeeds Dr. Stefan Lohmer, Axxam’s Co-Founder and CEO for the past 25 years. Dr. Lohmer will transition to the role of Board Member and Chairman of the Scientific Advisory Board, continuing to contribute his extensive expertise and visionary leadership to the company’s strategic direction.

Dr. Maraschiello brings over 25 years of experience in the Life Sciences Contract Research Service sector, with a strong operational management background, a proven track record of business transformation, and a specific expertise in preclinical and pharmaceutical development. Prior to joining Axxam in July 2023, he held leadership roles at Harlan Laboratories, Aptuit Inc. and Evotec SE, where he successfully developed and led R&D operations.

Commenting on his appointment, Ciriaco Maraschiello said: “I am honored and excited to be taking on the role of CEO. The company’s outstanding legacy of innovation and excellence in life sciences research is a testament to the vision of Stefan and the remarkable Axxam team. I look forward to building on this strong foundation and working closely with our talented team, partners, and clients to drive impactful solutions that address the challenges of today and tomorrow.”

Dr. Lohmer, who co-founded Axxam in 2001, has been instrumental in shaping the company’s trajectory, driving scientific advancements, and fostering a culture of collaboration and innovation.

Reflecting on his tenure, Dr. Lohmer said: “It has been an absolute privilege and a dream fulfilled to lead Axxam and work alongside so many talented and outstanding individuals over the past 25 years. The vision for Axxam remains consistent with its founding principles, but the company has reached a point in its journey where it is necessary to implement the next leadership generation who can further evolve our strategy and take the company to new heights. I am happy to support Ciriaco in his new role as CEO and confident he will deliver continued success. I am pleased to be staying very close to Axxam in the future through my role as Board Member and Chairman of the Scientific Advisory Board. I look forward to continuing to contribute to Axxam’s scientific excellence and evolution.”

This leadership transition marks an exciting new chapter for Axxam as it continues its mission to advance innovative research and deliver cutting-edge solutions in the Life Sciences industry.

About Axxam

Axxam is a leading Contract Research Organization (CRO) providing integrated early discovery services and solutions across the life sciences industries with headquarters and laboratories located in Bresso (Milan, Italy) and a subsidiary in Cambridge (Boston, USA). Within the drug discovery disciplines, Axxam supports pharma and biotech companies, start-ups, patient foundations as well as academic groups in their journey from target assessment and hit identification to lead generation across all therapeutic areas and target classes. Axxam’s services include assay development, hit identification and hit-to-lead. The same science-driven approach is also applied to identify new bioactive compounds for crop protection, animal health, food, beverage, pet food, cosmetic and perfume industries. For more information, please follow us on LinkedIn.

Download the press release in PDF format
Back
Scroll to Top